AMNEAL PHARMACEUTICALS, INC. (AMRX) Total liabilities 2017–2025
AMNEAL PHARMACEUTICALS, INC. (AMRX) total liabilities at each fiscal year-end, per SEC filings.
$3.7BFY2025 · since FY2017: $0 → $3.7B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.7B | +3.8% |
| FY2024 | $3.6B | +4.6% |
| FY2023 | $3.5B | -1.4% |
| FY2022 | $3.5B | -2.2% |
| FY2021 | $3.6B | -3.3% |
| FY2020 | $3.7B | +7.8% |
| FY2019 | $3.4B | -10.8% |
| FY2018 | $3.8B | — |
| FY2017 | $0 | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More AMRX financial trends
AMRX RevenueAMRX Net incomeAMRX Net marginAMRX Gross profitAMRX Gross marginAMRX Operating incomeAMRX Operating marginAMRX Operating cash flowAMRX Free cash flowAMRX Capital expendituresAMRX Return on equityAMRX Stock buybacksAMRX Dividends paidAMRX Total assetsAMRX Shareholders’ equityAMRX overview →